- A small retrospective study suggests that methotrexate (MTX) is an effective and well-tolerated treatment for children with moderate-to-severe nummular eczema.
Why this matters
- This study adds to the limited data concerning use of systemic therapy for nummular eczema in children.
- Median treatment duration was 12.6 months, and 50% of patients were still undergoing methotrexate treatment at the final review.
- At final clinical examination (mean, 13.4 months; median, 9.4 months), 35.7% of patients experienced >90% clearance, 46.4% of patients experienced 50%-89% clearance, 14.3% of patients experienced
- 21.4% of patients experienced gastrointestinal intolerance and 17.9% experienced a nonsignificant increase in liver enzymes.
- No serious adverse events were documented.
- 28 children with nummular eczema were treated with methotrexate and analyzed for efficacy and safety outcomes.
- Funding: None disclosed.
- Very small patient sample size.
- Retrospective study design.
- No control group.
- Topical corticosteroids were also used during study period.